Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... The majority of CML patients initially respond well to treatments with drugs called tyrosinekinase inhibitors (TKIs). However, a significant proportion of patients fail, or become ... FDA, Hematology, Imatinib, Myeloid Leukemia, Oncology, Pharmaceuticals, Protein Kinase Inhibitor, Regulatory Actions, Therapy, Treatment, U.S. Food and Drug Administration, ChemGenex ...
2009 NOV 23 ... to potentiate glucose-stimulated insulin secretion (GSIS). Inhibitory activity on tyrosinekinase or activation of protein kinase A (PKA) was shown to play a role in the ... secretion, but this was not sufficient to inhibit the activity of tyrosine kinase. Inhibitor studies as well as immunoblotting analysis demonstrated that activation of PKA was ...
2009 NOV 23 ... "Tyrosine phosphorylation is important in signaling pathways underlying tumorigenesis. We ... underlying tumorigenesis. We performed a mutational analysis of the protein tyrosine kinase (PTK) gene family in cutaneous metastatic melanoma," researchers in the United States ... reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib," wrote T.D. Prickett and colleagues, National Institutes of Health. ...
2009 NOV 16 ... insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are receptor tyrosine kinases that participate in mitogenic and antiapoptotic signaling in normal and ... of serum-starved AML cell lines. Conversely, treatment with BMS-536924, a dual IGF1R/IR kinaseinhibitor that is undergoing preclinical testing, inhibited constitutive receptor ...
2009 NOV 16 ... to a study from the United States, "The c-abl proto-oncogene encodes a nonreceptor tyrosinekinase involved in many cellular processes, including signaling from growth factor and ... MEFs are less responsive to induction of NF-kappa B activity by trichostatin A, an HDAC inhibitor, suggesting that c-Abl might play a role in the HDAC-mediated repression of basal ...
2009 NOV 23 ... as endothelial cells. The expression of insulin receptors was low, but insulin increased tyrosine phosphorylation of both the insulin receptor and insulin receptor substrate (IRS)-1 and ... both the insulin receptor and insulin receptor substrate (IRS)-1 and activated protein kinase B (PKB). The IRS-1 protein expression was reduced and the serine phosphorylation of PKB ... of mitogen-activated protein kinase (MAPK), an effect antagonized by the MEK-1 inhibitor PD98059. Furthermore, the endothelin ETA and ETB receptor antagonists BQ123 and BQ788 ...
2009 NOV 23 ... (CML) disease progression and its detection in late chronic-phase CML patients before tyrosine kinase inhibitor therapy was associated with poorer therapeutic responses and ABL tyrosine kinase domain ...
2009 NOV 23 ... (A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. Angiogenesis, 2009;12(3):287-296). ...
2009 NOV 23 ... there is growing concern for resistance to imatinib and to subsequent second generation tyrosinekinase inhibitors (dasatinib and nilotinib) due to the T315I mutation. With no currently ... Leukemia, Myeloid Leukemia, Nilotinib, Oncology, Pharmaceuticals, Protein Kinase Inhibitor, Proteomics. Fusion Proteins, Sprycel, Therapy, Treatment, Tyrosine Kinase. ...
2009 NOV 16 ... cells. The formation of the clusters could be completely blocked by adding a c-kit/tyrosine kinase inhibitor, Gleevec (imatinib mesylate; Novartis International, Basel, Switzerland, ...
2009 NOV 24 ... and in Matrigel implants. Furthermore, two small molecule inhibitors of the PDGFR tyrosinekinase (i.e., imatinib and dasatinib) exerted negative effects on fSMC and mSMC growth ... States, Life Sciences, Leiomyoma, Imatinib, Antineoplastic, Protein Kinase Inhibitor, Dasatinib, Sprycel, Reproduction. This article was prepared by Life ...
2009 NOV 16 ... cycle. In response to hepatocyte growth factor stimulation, Crk prominently induced the tyrosine phosphorylation of Grb2-associated binder 1 through activation of Src and focal adhesion ... Crk-induced activation of Src and subsequent signaling by p38 mitogen-activated protein kinase (MAPK) contribute to the enhanced proliferation of human synovial sarcoma cells. ... binder 1 through activation of Src and focal adhesion kinase, and the Src family kinase inhibitor PP2 almost completely inhibited the proliferation of SYO-1 cells. Crk also induced the ...
2009 NOV 16 ... According to recent research from Cachan, France, "Kit is a cell surface type III tyrosinekinase (TK) receptor implicated in cell transformation through overexpression or ... was clearly correlated to the inhibition of TK activity because imatinib, a specific inhibitor of the V560G mutant, inactive on the catalytic D816V mutant, induced only the ...
2009 NOV 23 ... study was designed to determine the effects of vandetanib, a small-molecule receptor tyrosine kinase inhibitor of vascular endothelial growth factor and epidermal growth factor receptor, on ...
2009 NOV 16 ... & Experimental Allergy. According to recent research from Vienna, Austria, "KIT tyrosinekinase inhibitors (TKI), such as nilotinib or midostaurin (PKC412), are increasingly ... in the MC leukaemia cell line HMC-1 and the basophil cell line KU812. The multi-kinase inhibitor midostaurin that interacts with KIT and protein kinase C was found to counteract ...
2009 NOV 16 ... States, "Epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosinekinase involved in the etiology of several human cancers. Cetuximab is an EGFR-blocking ... by the Src family kinases (SFK). Treatment of cetuximab-resistant cells with the SFK inhibitor, dasatinib, resulted in loss of nuclear EGFR, increased membrane expression of the EGFR ...
2009 NOV 16 ... of therapy, Waldenstrom macroglobulinemia is still incurable." "Src tyrosinekinase has been shown to play a central role in the regulation of a variety of ... in Waldenstrom macroglobulinemia and normal cells, and the effect of the specific Src inhibitor AZD0530 on the adhesion, migration, cell cycle, and survival of a Waldenstrom ...
2009 NOV 23 ... "In cell lines, upon cisplatin treatment, c-Abl phosphorylates TAp63 on specific tyrosine residues. Such modifications affect p63 stability and induce a p63-dependent activation ... rapidly promotes TAp63 accumulation and eventually cell death. Treatment with the c-Abl kinaseinhibitor imatinib counteracts these cisplatin-induced effects. Taken together, these ...
2009 NOV 16 ... "Sunitinib, a multiple receptor tyrosine kinase inhibitor, is used in the treatment of renal cell carcinoma and gastrointestinal stromal tumors," ...
